Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 524-532

  Van Binnendijk, Robert S ^a   Poelen, Martien C M ^b   Van Amerongen, Geert ^b   De Vries, Petra ^b   Osterhaus, Albert D M E ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MATERNAL ANTIBODY; MEASLES VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE;

ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; HOST RESISTANCE; IMMUNOREACTIVITY; MACACA; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031027893     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.524     Document Type: Article

References (31)

1. Norrby E. Immunobiology of paramyxoviruses. In: Kingsbury DW, ed. The paramyxoviruses. New York: Plenum Press, 1991:481-507.
2. Gellin BG, Katz SL. Measles: state of the art and future directions. J Infect Dis 1994;170(suppl 1):S3-S14.
3. UytdeHaag FGCM, Van Binnendijk RS, Kenter MJH, Osterhaus ADME. Cytotoxic T lymphocyte responses against measles virus. In: Oldstone MBA, ed. Cytotoxic T-lymphocytes in human viral and malaria infections. Berlin: Springer-Verlag, 1994:151-67.
4. Griffin DE. Immune responses during measles virus infection. Curr Top Microbiol Immunol 1995;191:117-34.
5. Clements CJ, Cutts FT. The epidemiology of measles: thirty years of vaccination. Curr Top Microbiol Immunol 1995;191:13-33.
6. Ward BJ, Griffin DE. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin Immunol Immunopathol 1993;67:171-7.
7. Enders JF, Katz SL, Milovanovic MV, Holloway A. Studies on an attenuated measles-virus vaccine I. Development and preparation of the vaccine: techniques for assay of effects of vaccination. N Engl J Med 1960;263:153-9.
8. Van Binnendijk RS, van der Heijden RWJ, Van Amerongen G, UytdeHaag FGCM, Osterhaus ADME. Viral replication and development of specific immunity in macaques after infection with different measles virus strains. J Infect Dis 1994;170:443-8.
9. Expanded Programme on Immunization. Measles control in the 1990s: plan of action for global measles control. Geneva: World Health Organization, 1992:1-34; document WHO/EPI/GEN/92.3.
10. Katz SL, Gellin BG. Measles vaccine: do we need new vaccines or new programs. Science 1994;265:1391-2.
11. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977;91:715-8.
12. Halsey NA, Boulos R, Mode R, et al. Response to measles vaccine in Haitian infants 6 to 12 months old. N Engl J Med 1985;313:544-9.
13. Markowitz LE, Sepulveda J, Diaz-Ortega JL, et al. Immunization of sixmonth-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 1990;322:580-7.
14. Gustafson TL, Lievens AW, Brunnel PA, Moellenberg RG, Buttery CMC, Schulster LM. Measles outbreak in a fully immunized secondary-school population. N Engl J Med 1987;316:771-4.
15. Pedersen IR, Mordhorst CH, Glikmann G, Magnus von H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine 1989;7:345-8.
16. Markowitz LE, Preblud SR, Orenstein WA, et al. Patterns of transmission in measles outbreaks in the United States, 1985-1986. N Engl J Med 1989;320:75-81.
17. Mathias R, Meekison J, Arcan T, Schechter M. The role of secondary vaccine failures in measles outbreaks. Am J Public Health 1989;79:475-8.
18. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990;162:1036-42.
19. Osterhaus ADME, De Vries P, Van Binnendijk RS. Measles vaccines: novel generations and new strategies. J Infect Dis 1994;170(suppl 1):S42-55.
20. Job JS, Halsey NA, Boulos R, et al. Successful immunization of infants at 6 months of age with high dose Edmonston-Zagreb measles vaccine. Pediatr Infect Dis J 1991;10:303-11.
21. Garenne M, Leroy O, Beau JP, Sene I. Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 1991;338:903-7.
22. Wild TF, Bernard A, Spehner D, Drillien R. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice. J Gen Virol 1992;73:359-67.
23. De Vries P, Van Binnendijk RS, Van De Marel P, et al. Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells, and protection in mice. J Gen Virol 1988;69:549-59.
24. Erdman DD, Anderson LJ, Adams DR, Stewart JA, Markowitz LE, Bellini WJ. Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus. J Clin Microbiol 1991;29:1466-71.
25. Van Binnendijk RS, Poelen MCM, Kuijpers KC, Osterhaus ADME, UytdeHaag FGCM. The predominance of CDS T cells after infection with measles virus suggests a role for CDS class I MHC-restricted cytotoxic T lymphocytes (CTL) in recovery from measles. J Immunol 1990;144:2394-9.
26. Galetti R, Beauverger P, Wild TF. Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses. Vaccine 1995;13:197-201.
27. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 1988;62:3907-10.
28. Fenner F, Henderson DA, Arita I, Jezek Z, Lodgni ID. The effectiveness of vaccinia in the face of passively transferred antibody has been demonstrated in the smallpox eradication program. In: Smallpox: its eradication. Geneva: World Health Organization, 1998:293-4.
29. Fujinami RS, Oldstone MB. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 1979;279:529-30.
30. Wu VH, McFarland H, Mayo K, Hanger L, Griffin DE, Dhib-Jalbut S. Measles virus specific cellular immunity in patients with vaccine failure. J Clin Microbiol 1993;31:118-22.
31. Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, Deserres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995;172:1591-5.